8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

CURRENT REPORT

FORM 8-K

Pursuant to Section 13 or 15(d) of the Securities Exchange Act

Date of Report (Date of Earliest Event Reported): November 14, 2012

Hanger, Inc.

(Exact name of registrant as specified in its charter)

Delaware	1-10670	84-0904275
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of incorporation)		Identification No.)

Formerly Hanger Orthopedic Group, Inc.

10910 Domain Drive, Suite 300

Austin, Texas 78758

(Address of principal executive offices (zip code))

512-777-3800

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a - 12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))

Item 7.01.  Regulation FD Disclosure

From time to time, Hanger, Inc. (“we”, “our” or the “Company”) makes presentations to the investment community. The current version of our investment community presentation materials are furnished as Exhibit 99.1 to this Form 8-K and are posted under the investor relations section of our website (www.hanger.com). This information is furnished pursuant to Item 7.01 of Form 8-K and Regulation FD, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, unless we specifically incorporate it by reference in a document filed under the Securities Act of 1933 or the Securities Exchange Act of 1934. By filing this report on Form 8-K and furnishing this information, we make no admission as to the materiality of any information in this report.

The information contained in the presentation materials is summary information that is intended to be considered in the context of our filings with the Securities and Exchange Commission (“SEC”) and other public announcements that we may make, by press release or otherwise, from time to time. We undertake no duty or obligation to publicly update or revise the information contained in this report, although we may do so from time to time as our management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

Certain expectations and projections regarding the future performance of the Company referenced in the exhibit to this report are “forward-looking statements” as provided in the United States Private Securities Litigation Reform Act of 1995.  These expectations and projections are based on currently available competitive, financial, and economic data, along with the Company’s operating plans.  However, various risks, uncertainties and contingencies could cause actual results or performance to differ materially from those expressed in, or implied by, these statements, including the Company’s ability to enter into and derive benefits from managed care contracts, the demand for the Company’s orthotic and prosthetic services and products and the other factors identified in the Company’s periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934. We caution readers that in addition to the above cautionary statements, all forward-looking statements contained herein should be read in conjunction with our SEC filings and other public releases or disclosures.

Item 9.01.      Financial Statements and Exhibits

(d)Exhibits.

99.1November 2012 Investment Community Presentation Materials

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HANGER, INC.

By:	/s/George E. McHenry
		George E. McHenry
		Chief Financial Officer

Dated:  November 14, 2012

3

Hanger, Inc.

Exhibit Index to Current Report on Form 8-K

Dated February 28, 2012

Exhibit
Number
99.1	November 2012 Investment Community Presentation Materials

4

EX-99.1

Exhibit 99.1

150 YEARS Investor Presentation of Empowering Human Potential. November 2012

SAFE HARBOR Except for the historical information contained herein, the matters discussed in this presentation constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected. These include the rate at which Hanger grows same-center net sales, competitive pressures within the industry, government regulation and reimbursement, and other factors discussed from time to time in the reports filed by the company with the Securities and Exchange Commission. The company assumes no obligation to update information contained in this presentation. 1

VISION Be the partner of choice for products and services that enhance human physical capability. 2

OVERVIEW 3 $961 million in revenues LTM Adjusted EBITDA $159 million LTM

OVERVIEW 4 DISTRIBUTION 11% of revenues LTM $106 million revenue LTM THERAPEUTIC SOLUTIONS 7 % of revenues LTM $63 million revenue LTM ACP, Inc. IN, Inc. PATIENT CARE 82 % of revenues LTM $792 million revenue LTM Linkia $961 million in revenues LTM Adjusted EBITDA $159 million LTM

OVERVIEW 5 $961 million in revenues LTM Adjusted EBITDA $159 million LTM THERAPEUTIC SOLUTIONS 7 % of revenues LTM $63 million revenue LTM ACP, Inc. IN, Inc. DISTRIBUTION 11% of revenues LTM $106 million revenue LTM PATIENT CARE 82 % of revenues LTM $792 million revenue LTM Linkia

OVERVIEW 6 $961 million in revenues LTM Adjusted EBITDA $159 million LTM THERAPEUTIC SOLUTIONS 7 % of revenues LTM $63 million revenue LTM ACP, Inc. IN, Inc. DISTRIBUTION 11% of revenues LTM $106 million revenue LTM PATIENT CARE 82 % of revenues LTM $792 million revenue LTM Linkia

PATIENT CARE 7

8 PROFILE PATIENT CARE One or more certified clinicians Technical personnel Office administrators Line of site incentives to grow revenues and collect receivables CAGR up 6.7% (2008–2011) Business Overview Center Overview Over 730 O&P patient-care centers Over 1,200 O&P certified and licensed clinicians Stand alone—design, fabricate and fit Treat more than 1,000,000 patients annually

9 MARKET POSITION PATIENT CARE Only national or regional provider Hanger operates ~18% of accredited O&P facilities No other provider has more than 2% market share $4.3 Billion Total Addressable Market $2.6 Billion Traditional Custom O&P Market Hanger 17%

PATIENT CARE REIMBURSEMENT SOURCES 10

COMPELLING GROWTH DRIVERS 11 Sources: Company estimates; Wall Street Research; 2003–2006 National Health and Nutrition Examination Survey; National Institutes of Health; Amputee Coalition of America. Aging Population (U.S.) (%) Diabetes – Prevalence By Age Group Disease and aging population Advancing technology Regulatory reform Increased focus on lowering costs

PATIENT CARE First to market with new technologies and products Linkia Network Management Diversification into new adjacent businesses CARES Dosteon Solutions Small O&P acquisitions Sales synergies with ACP 12 GROWTH OPPORTUNITIES

LINKIA First and only O&P network management company Insurers’ exclusive or preferred provider of their network Hanger network of approximately 1,070 O&P centers 53 contracts; 1–3 years; auto renew Value proposition to large name companies through expanded services 28% CAGR of contracted revenues (2008–2011) 13 NETWORK MANAGEMENT

DISTRIBUTION 14

DISTRIBUTION Largest dedicated distributor of O&P devices and components Over 29,000 O&P related items 6 strategically located distribution facilities Comprehensive Customer Service Manufacture and distribute therapeutic footwear Net sales $106 million LTM and CAGR of 7.6% (2008–2011) Inter-company sales $207 million LTM 15 PROFILE

DISTRIBUTION Increase depth and breadth of product line Increase penetration of existing customer base Expand customer base Expand market presence geographically Apply core competencies to adjacent businesses Expand O&P fabrication operation to Independent O&P Providers 16 OPPORTUNITIES

THERAPEUTIC SOLUTIONS 17

THERAPEUTIC SOLUTIONS Innovative Neurotronics Development and commercialization of products V-Hold and WalkAid Accelerated Care Plus (ACP) Value proposition to rehabilitation providers Technology, clinical modalities, training and education 18 DIVERSIFICATION OF REVENUE

ACP OVERVIEW 19 ACP enables post-acute providers with 24 evidence-based clinical therapy programs including: Physical Agent Modality Basics Wound Healing Fall Prevention Continence Improvement Contracture Management Pain Management Physical Agent Modality Basics Osteoarthritis of the Knee Orthotic Therapy Hemiplegic Gait Chronic Obstructive Pulmonary Disease Electrode Application & Safety Rheumatoid Arthritis of Wrist & Hand Stroke – Hand Edema Stroke Recovery Herpes Zoster (Shingles) Sports & Orthopedic Rehabilitation PRE’s with Elastic Bands Aerobic Exercise for Aging Adults PAM Documentation Recommendations Clients facility’s standard equipment package OMNISTIM® 500 AND OMNISTIM® FX2 ELECTRICAL STIMULATION OMNISOUND® 300 ULTRASOUND MEGAPULSE® SHORTWAVE DIATHERMY OMNICYCLE® MOTOR ASSISTED CYCLE Monthly Supplies

FINANCIAL OVERVIEW 20

SOLID FINANCIAL POSITION Earnings and margin growth Substantial cash flow generation Strong balance sheet management Moderate leverage post ACP acquisition Consistent reduction of leverage 21

Q3 2012 IN REVIEW 1% growth in Same Stores Sales 12.5% growth in Adjusted EBITDA 11.1% increase in earnings per share Leverage ratio to 2.82X Total liquidity at 9/30/2012 was $155.12 Million including $55.62 of cash Total Debt $509.0 Million 22

REVENUE GROWTH 23 ($ in millions)

ADJUSTED EBITDA GROWTH AND MARGINS* 24 CAGR 16.4% Excludes relocation expenses and cost related to acquisitions. Adjusted EBITDA Adjusted EBITDA Margins % ($ in millions)

GROWTH IN ADJUSTED EPS* 25 * Excludes relocation expenses, cost related acquisitions and the accelerated non-cash preferred dividend in 2008. ($ in millions)

STEADY COMPARABLE QUARTER GROWTH 26 2010 2011 2012 2009 Adjusted EBITDA* ($ in millions) * Excludes relocation expenses and cost related to the ACP acquisition. Revenues ($ in millions) Adjusted Earnings Per Diluted Share* * Excludes relocation expenses, cost related to the ACP acquisition and accelerated non-cash preferred dividend. $0.00 $0.10 $0.20 $0.30 $0.40 $0.50 $0.60 Q1 Q2 Q3 Q4 $155 $175 $195 $215 $235 $255 Q1 Q2 Q3 Q4 $15 $25 $35 $45 Q1 Q2 Q3 Q4

KEY INVESTMENT POINTS Compelling industry growth drivers Dominant market position Attractive organic growth opportunities Adjacent continuum of care opportunities Proven acquisition capabilities Solid financial position 27

(NYSE: HGR) 28